Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States.
The last earnings update was 5 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Plus Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Plus Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Plus Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Plus Therapeutics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Plus Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Plus Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Plus Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Plus Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Plus Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 1.8x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Marc H. Hedrick, M.D., has been the President of Plus Therapeutics, Inc. (also known as Cytori Therapeutics, Inc. and Macropore Biosurgery Inc.) since May 2004 and has been its Chief Executive Officer since April 2, 2014. Dr. Hedrick had been Principal Financial and Accounting Officer at Plus Therapeutics, Inc. since August 09, 2019 until November 6, 2019. Dr. Hedrick served as the Principal Financial Officer of Cytori Therapeutics, Inc. from August 2014 to September 2, 2014. Dr. Hedrick joined Cytori Therapeutics, Inc. as the Chief Scientific Officer and Medical Director in October 2002. He co-founded StemSource Inc. and served as the President and Chief Executive Officer and Director. He is a Plastic Surgeon and was an Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA) and From 1998 to 2005, has directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick has been a Director of Cytori Therapeutics, Inc. since October 2002. He obtained his MD degree from the University of Texas Southwestern Medical School, Dallas and an M.B.A. from UCLA Anderson School of Management.
Marc's compensation has been consistent with company performance over the past year, both up more than 20%.
Marc's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Plus Therapeutics management team is less than 2 years, this suggests a new team.
VP of Finance & CFO
Vice President of Marketing
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Plus Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Independent Chairman of the Board
An van Es-Johansson
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company’s lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. It also engages in developing DoxoPLUS, an injectable generic PEGylated liposomal formulation of doxorubicin for the treatment of breast, ovarian, multiple myeloma, and Kaposi’s sarcoma cancer. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.